20-06-2022 | EULAR 2022 | Conference coverage | Video
BE MOBILE 1 and 2: How might bimekizumab impact axSpA clinical practice?
Fabian Proft discusses the potential impact of bimekizumab on the treatment of radiographic and nonradiographic axial spondyloarthritis in light of findings from the BE MOBILE 1 and 2 trials (3:02).